Stock A215600 SILLAJEN, INC.
Add to a list
To use this feature you must be a member
Log inSign up

SillaJen, Inc.

Equities

A215600

KR7215600008

Biotechnology & Medical Research

End-of-day quote Korea S.E.
Other stock markets
 18:00:00 2024-05-16 EDT 		5-day change 1st Jan Change
4,655 KRW +1.97% Intraday chart for SillaJen, Inc. +7.63% -22.80%
04-22 OSR Holdings and SillaJen Enter into A Memorandum of Understanding to Collaborate the Development of Innovative Therapeutics and Enter the U.S. Market CI
03-27 SillaJen, Inc. Submits CSR to the US FDA for REN026 Study in Patients with RCC CI

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration

Latest news about SillaJen, Inc.

OSR Holdings and SillaJen Enter into A Memorandum of Understanding to Collaborate the Development of Innovative Therapeutics and Enter the U.S. Market CI
SillaJen, Inc. Submits CSR to the US FDA for REN026 Study in Patients with RCC CI
SillaJen to Raise 129.4 Billion Won via Shares Issuance MT
SillaJen, Inc.(KOSDAQ:A215600) added to S&P Global BMI Index CI
Switzerland's Basilea Pharmaceutica Secures $4 Million Milestone Payment for Oncology Asset MT
SillaJen Resumes Trading on Kosdaq MT
SillaJen Bags Licensing Right to Basilea Pharmaceutica's Oncology Drug MT
Kosdaq Delists Biotechnology Company SillaJen MT
An unknown buyer agreed to acquire a 5.1% stake in NeoImmuneTech, Inc. from SillaJen, Inc. for KRW 10.1 billion. CI
SillaJen, Inc. announced that it has received KRW 40 billion in funding CI
SillaJen, Inc. announced that it has received KRW 60 billion in funding from M2N Co.,Ltd CI
SillaJen, Inc. announced that it expects to receive KRW 40 billion in funding CI
SillaJen, Inc. announced that it expects to receive KRW 60 billion in funding from M2N Co.,Ltd CI
M2N Co.,Ltd signed LOI to acquire SillaJen, Inc.. CI
SillaJen, Inc.(KOSDAQ:A215600) dropped from S&P Global BMI Index CI
SillaJen, Inc.(KOSDAQ:A215600) dropped from FTSE All-World Index CI
SillaJen, Inc. announced that it has received KRW 20 billion in funding CI
SillaJen, Inc. announced that it expects to receive KRW 20 billion in funding CI
Sillajen Announces Conclusions from Interim Futility Analysis of Phase 3 PHOCUS Trial in HCC CI
SillaJen Announces First Patient Enrolled in Part 2 of Renal Cell Carcinoma Trial with Pexa-Vec in Combination with Regeneron's Libtayo® (cemiplimab-rwlc) CI
SillaJen, Inc. announced that it has received KRW 110 billion in funding CI
SillaJen, Inc. announced that it expects to receive KRW 110 billion in funding CI
SillaJen, Inc. Announces First Patient Enrolled in Renal Cell Carcinoma Trial with Pexa-Vec in Combination with Regeneron's Cemiplimab CI
SillaJen, Inc.(KOSDAQ:A215600) added to FTSE All-World Index CI
SillaJen, Inc.(KOSDAQ:A215600) added to FTSE All-World Index CI

Chart SillaJen, Inc.

Chart SillaJen, Inc.
More charts

Company Profile

SillaJen Inc is a Korea-based company primarily engaged in the research and development of oncolytic virus immunotherapeutics. The Company’s major product is Pexa-Vec, which is in a global Phase 3 clinical trial that is used for the treatment of liver cancer. Additionally, it also offers oncolytic virus immunotherapeutics, including SJ-102, SJ-103, SJ-815, JX-929, JX-930, JX-963, JX-970 and others.970 and others.
Sector
Biotechnology & Medical Research
Calendar
2024-08-12 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

1st Jan change Capi.
SILLAJEN, INC. Stock SillaJen, Inc.
-22.80% 354M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+9.42% 115B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+11.84% 106B
ARGENX SE Stock argenx SE
-1.05% 21.96B
BIONTECH SE Stock BioNTech SE
-14.15% 21.84B
GENMAB A/S Stock Genmab A/S
-5.29% 19.21B
BEIGENE, LTD. Stock BeiGene, Ltd.
-4.16% 18.08B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.29% 17.71B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+7.99% 14.32B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+36.24% 12.42B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. A215600 Stock
  4. News SillaJen, Inc.
  5. SillaJen Resumes Trading on Kosdaq
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW